Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D02EVF
|
|||
| Former ID |
DNCL002955
|
|||
| Drug Name |
Losartan/thioctic acid
|
|||
| Synonyms |
Lipoic acid; lipoic acid; 1200-22-2; (R)-lipoic acid; R-(+)-alpha-Lipoic acid; (R)-5-(1,2-Dithiolan-3-yl)pentanoic acid; Heparlipon; Thioctic acid d-form; (R)-(+)-1,2-Dithiolane-3-pentanoic acid; R-alpha-Lipoic acid; (R)-1,2-Dithiolane-3-pentanoic acid; Tioctic Acid; D-Thioctic acid; R-(+)-Thioctic acid; (R)-alpha-Lipoic acid; (R)-(+)-lipoic acid; (R)-6,8-thioctic acid; lipoate; (R)-1,2-Dithiolane-3-valeric Acid; 5-[(3R)-1,2-dithiolan-3-yl]pentanoic acid; (R)-(+)-Lipoate; UNII-VLL71EBS9Z; R-Lipoic acid; INV-144
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Diabetic nephropathy [ICD-11: GB61.Z; ICD-9: 250.4] | Phase 2 | [1] | |
| Company |
InVasc Therapeutics
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C8H14O2S2
|
|||
| Canonical SMILES |
C1CSSC1CCCCC(=O)O
|
|||
| InChI |
1S/C8H14O2S2/c9-8(10)4-2-1-3-7-5-6-11-12-7/h7H,1-6H2,(H,9,10)/t7-/m1/s1
|
|||
| InChIKey |
AGBQKNBQESQNJD-SSDOTTSWSA-N
|
|||
| CAS Number |
CAS 1200-22-2
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID |
599062, 4265946, 6436518, 7888683, 8026908, 8028221, 8146183, 8153826, 15171829, 15171830, 17405685, 24881001, 25644196, 29215172, 29225119, 47205549, 48393936, 49834021, 50107042, 50107043, 53778235, 57323196, 78866725, 87325086, 87559792, 90340763, 92303296, 92710523, 103372397, 104002199, 104311154, 121361803, 124750257, 124891689, 125311883, 126524063, 126608915, 126617398, 126631794, 126664379, 127401708, 131296196, 134345326, 135115683, 136379713, 136991607, 137005094, 142392119, 152032298, 152212195
|
|||
| ChEBI ID |
CHEBI:30314
|
|||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Therapeutic approaches to diabetic nephropathy--beyond the RAS. Nat Rev Nephrol. 2014 Jun;10(6):325-46. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.